<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798406</url>
  </required_header>
  <id_info>
    <org_study_id>2401BT-002P</org_study_id>
    <nct_id>NCT02798406</nct_id>
  </id_info>
  <brief_title>Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects</brief_title>
  <acronym>CAPTIVE</acronym>
  <official_title>A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DNAtrix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>DNAtrix, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant
      brain tumor in adults and can be resistant to conventional therapies. The purpose of this
      Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds
      to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered
      directly into the tumor followed by the administration of intravenous pembrolizumab (an
      immune checkpoint inhibitor) given every 3 weeks for up to 2 years or until disease
      progression.

      Funding Source-FDA OOPD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the initial phase of the study, up to 12 evaluable subjects will be enrolled in 3 dose
      cohorts to determine the best dose of DNX-2401, as follows:

        -  Cohort 1: Single dose DNX-2401 (5e8 vp) delivered intratumorally by cannula, followed by
           intravenous pembrolizumab every 3 weeks (Q3W)

        -  Cohort 2: Single dose DNX-2401(5e9 vp) delivered intratumorally by cannula, followed by
           intravenous pembrolizumab every 3 weeks (Q3W)

        -  Cohort 3: Single dose DNX-2401 (5e10 vp) delivered intratumorally by cannula, followed
           by intravenous pembrolizumab every 3 weeks (Q3W)

      Following the initial phase, up to 36 additional subjects diagnosed with recurrent
      glioblastoma or gliosarcoma will be enrolled to receive a single of DNX-2401 determined in
      the initial phase administered intratumorally followed by intravenous pembrolizumab every 3
      weeks.

      All subjects will return to the clinic for study follow-up visits at regular intervals for
      safety monitoring, MRI scans and other assessments, for up to 2 years or until disease
      progression. All subjects will be followed closely for safety and survival.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>3.5 years</time_frame>
    <description>Interval tumor size reduction as measured from periodic MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3.5 years</time_frame>
    <description>Months alive following treatment as measured during periodic study visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor response</measure>
    <time_frame>3.5 years</time_frame>
    <description>Months to response following treatment as measured during periodic MRIs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>3.5 years</time_frame>
    <description>Months of sustained response as measured during periodic study visits</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Brain Cancer</condition>
  <condition>Brain Neoplasm</condition>
  <condition>Glioma</condition>
  <condition>Glioblastoma</condition>
  <condition>Gliosarcoma</condition>
  <condition>Malignant Brain Tumor</condition>
  <condition>Neoplasm, Neuroepithelial</condition>
  <condition>Neuroectodermal Tumors</condition>
  <condition>Neoplasm by Histologic Type</condition>
  <condition>Neoplasm, Nerve Tissue</condition>
  <condition>Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>DNX-2401 + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral dose (1.0 mL) of DNX-2401 followed 7-9 days later by intravenous pembrolizumab, 200 mg, given every three weeks through 105 weeks (2 yrs.) or until progressive disease or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNX-2401</intervention_name>
    <description>On Day 0, following brain tumor biopsy and confirmation of recurrent tumor, a single injection of DNX-2401 is administered directly into the brain tumor.</description>
    <arm_group_label>DNX-2401 + pembrolizumab</arm_group_label>
    <other_name>Oncolytic virus</other_name>
    <other_name>Genetically-modified adenovirus</other_name>
    <other_name>Delta-24</other_name>
    <other_name>Delta-24-RGD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>Sequential intravenous administration every three weeks beginning 7-9 days after Day 0/DNX-2401</description>
    <arm_group_label>DNX-2401 + pembrolizumab</arm_group_label>
    <other_name>KEYTRUDA</other_name>
    <other_name>lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
    <other_name>Checkpoint inhibitor</other_name>
    <other_name>monoclonal antibody</other_name>
    <other_name>anti-PD1/PD-L1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A single glioblastoma or gliosarcoma tumor with histopathological confirmation for
             first or presenting second recurrence of glioblastoma or gliosarcoma at the time of
             consent

          -  Gross total or partial tumor resection is not possible or not planned

          -  A single measurable tumor that is at least 10.0 mm longest diameter (LDi) X 10.0 mm
             shortest diameter (SDi) and this tumor does not exceed 40.0 mm in LDi or SDi on
             Screening MRI

          -  Tumor recurrence or progression documented after previously failing surgical
             resection, chemotherapy or radiation

          -  Karnofsky performance status ≥ 70 %

          -  Prior anti-tumor therapies must have been completed within time periods specified in
             the protocol prior to DNX-2401 injection and toxic side effects must be mild, if
             present

          -  Demonstrate adequate organ function via specified laboratory test results

        Exclusion Criteria:

          -  Multiple (≥ 2) separate enhancing tumors

          -  Tumor location on both sides of the brain and/or involvement that would present the
             risk of injecting DNX-2401 into the ventricles of the brain

          -  Tumor location in the brain stem

          -  Requires or, based upon history, may require treatment with high-dose systemic
             corticosteroids within 2 weeks of the start of intravenous pembrolizumab infusions and
             within 2 weeks following the first infusion of pembrolizumab

          -  Uncontrolled blood-sugar levels defined as HbA1c &gt; 7%

          -  Previous treatment with any checkpoint inhibitor such as anti-PD1 or PD-L1 agents
             including pembrolizumab (KEYTRUDA) or any other checkpoint inhibitor(s) (e.g.,
             ipilimumab, nivolumab, etc.)

          -  History of (non-infectious) or current active pneumonitis that required steroids
             and/or a history of interstitial lung disease

          -  Prior gene transfer therapy or prior therapy with a cytolytic virus of any type

          -  Brain tumor that is not measurable on MRI or persons who are unable to have MRIs

          -  Pregnant or nursing females

        Note: Other protocol-defined inclusion and exclusion criteria may apply as outlined in the
        relevant protocol version
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matteo Levisetti, MD</last_name>
    <role>Study Director</role>
    <affiliation>DNAtrix, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences (UAMS)</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Neurosurgery</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill-Cornell Medicine New York-Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University James Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Austin-Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>December 28, 2019</last_update_submitted>
  <last_update_submitted_qc>December 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brain</keyword>
  <keyword>Central Nervous System (CNS) diseases</keyword>
  <keyword>Central Nervous System (CNS) neoplasms</keyword>
  <keyword>CNS</keyword>
  <keyword>conditionally replicative adenovirus</keyword>
  <keyword>DNX-2401</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>KEYTRUDA</keyword>
  <keyword>MK-3475</keyword>
  <keyword>SCH 900475</keyword>
  <keyword>lambrolizumab</keyword>
  <keyword>neoplasm, germ cell and embryonal</keyword>
  <keyword>neoplasm, granular and epithelial</keyword>
  <keyword>Alcyone</keyword>
  <keyword>Alcyone Lifesciences</keyword>
  <keyword>AMC</keyword>
  <keyword>cannula</keyword>
  <keyword>MEMS cannula</keyword>
  <keyword>DNX-2401 + pembrolizumab</keyword>
  <keyword>Delta-24</keyword>
  <keyword>Delta-24-RGD</keyword>
  <keyword>Checkpoint inhibitor</keyword>
  <keyword>anti-PD1/PD-L1</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>KEYNOTE-192</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoviridae Infections</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Neoplasms by Histologic Type</mesh_term>
    <mesh_term>Neoplasms, Nerve Tissue</mesh_term>
    <mesh_term>Neoplasms, Neuroepithelial</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Plan to share aggregate data at completion of study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

